Published in Hepatitis Weekly, July 14th, 2003
This knowledge should help clinicians predict the effectiveness of individual treatments and consequently decide who should go through such a regimen.
Jennifer Layden-Almer, leading the clinical study at the Department of Medicine, University of Illinois, Chicago, and Ruy Ribeiro, of the Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, USA, and Oxford University, U.K., responsible for the mathematical modeling, show that in African Americans, a group...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.